Cancer News

Many Late Stage Lung Cancer Patients do not Receive Treatment (01/24/2017)

A national study by researchers at UC Davis Comprehensive Cancer Center has found that a significant number of lung cancer patients are not receiving treatment. Based on data between 1998 and 2012 from the National Cancer Database, 21 percent of patients (190,539) with non-small cell lung cancer (NSCLC) received no specific cancer treatment, such as …

Continue reading "Many Late Stage Lung Cancer Patients do not Receive Treatment"

Keytruda® Active in Small Cell Lung Cancer (12/27/2016)

Recently updated findings from the phase 1b KEYNOTE-028 study investigating the use of Keytruda® (pembrolizumab) in small cell lung cancer (SCLC) were recently presented at the 17th World Conference on Lung Cancer. Lung cancer remains the leading cause of cancer-related deaths worldwide. In the United States, SCLC accounts for 10-20% of all lung cancers. Although progress … Continue reading "Keytruda® Active in Small Cell Lung Cancer"

Tagrisso®: New Standard of Care for Certain Lung Cancer (12/19/2016)

Treatment with the targeted agent Tagrisso (osimertinib) significantly delayed cancer progression, and resulted in fewer side effects, than standard chemotherapy for patients with advanced non-small cell lung cancer (NSCLC) whose cancer had progressed following prior therapy with an epidermal growth factor receptor (EGFR) inhibitor. Lung cancer remains the leading cause of cancer-related deaths in the … Continue reading "Tagrisso®: New Standard of Care for Certain Lung Cancer"

Personalized Lung Cancer Care & Precision Medicine (11/08/2016)

Targeted and more-individualized treatment for NSCLC becomes a reality. Lung cancers used to be diagnosed solely by a visual microscopic examination of tumor tissue and all patients received the same chemotherapy. Now, doctors are personalizing care by finding the genetic alterations within the cancer that drive its growth and then use medicines that specifically counteract … Continue reading "Personalized Lung Cancer Care & Precision Medicine"

Precision Medicine Guides NSCLC Cancer Treatment: All Patients Should Undergo Molecular Testing (10/27/2016)

Lung cancer remains the leading cause of cancer-related deaths worldwide. In the United States, non-small cell lung cancer (NSCLC) accounts for 75–80% of all lung cancers. Although progress has been made in recent years, the majority of patients with advanced stage lung cancer still die from their disease. Precision medicine continues to impact the lives … Continue reading "Precision Medicine Guides NSCLC Cancer Treatment: All Patients Should Undergo Molecular Testing"

Tecentriq® Improves NSCLC Survival Compared to Chemotherapy Regardless of PD-L1 Status (10/25/2016)

Tecentriq® (atezolizumab) improves the outcomes of individuals with advanced non-small cell lung cancer (NSCLC) according to the results of a pivotal clinical trial presented at the European Society of Medical Oncology (ESMO) 2016 Annual Meeting this week. Tecentriq is an agent that stimulates the immune system to recognize and mount an immune attack against cancer … Continue reading "Tecentriq® Improves NSCLC Survival Compared to Chemotherapy Regardless of PD-L1 Status"

Immunotherapy May Become New Standard of Care in Advanced Non-Small Cell Lung Cancer (10/19/2016)

Researchers presented full results of Keytruda® (pembrolizumab) and Opdivo® (nivolumab) in previously untreated advanced non-small cell lung cancer (NSCLC) at the European Society for Medical Oncology annual meeting in Copenhagen. An additional study was also recently published in the New England Journal of Medicine evaluating Keytruda in previously treated patients with advanced NSCLC . Results of … Continue reading "Immunotherapy May Become New Standard of Care in Advanced Non-Small Cell Lung Cancer"

FDA Grants Breakthrough Therapy Designation to Keytruda® for First-Line Treatment of Patients with Advanced Non-Small Cell Lung Cancer (09/14/2016)

The U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for Keytruda® (pembrolizumab) for first-line treatment of patients with advanced non-small cell lung cancer (NSCLC). The FDA’s Breakthrough Therapy Designation is intended to expedite the development and review of a drug that is planned for use to treat a serious or life-threatening disease … Continue reading "FDA Grants Breakthrough Therapy Designation to Keytruda® for First-Line Treatment of Patients with Advanced Non-Small Cell Lung Cancer"

Whole-Brain Radiotherapy Fails to Benefit Most Patients with Lung Cancer (09/13/2016)

Whole-brain radiotherapy (WBRT) provides “little additional clinically significant benefit” for patients with non–small cell lung cancer (NSCLC) with brain metastases, according to doctors performing the first large-scale randomized controlled trial of its kind. As many as 30% of all patients with NSCLC will present with or develop brain metastases. There is currently a routine practice … Continue reading "Whole-Brain Radiotherapy Fails to Benefit Most Patients with Lung Cancer"